QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
NASDAQ:AVIR

Atea Pharmaceuticals Stock Forecast, Price & News

$12.17
-0.22 (-1.78 %)
(As of 10/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$11.91
$12.51
50-Day Range
$25.98
$44.59
52-Week Range
$10.76
$94.17
Volume
2.25 million shs
Average Volume
1.92 million shs
Market Capitalization
$1.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive AVIR News and Ratings via Email

Sign-up to receive the latest news and ratings for Atea Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Atea Pharmaceuticals logo

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase I/IIa clinical trial for the treatment of chronic hepatitis C; and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus. It has a Roche License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. for development and commercialization related to AT-527 outside of the United States. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVIR
Employees
39
Year Founded
N/A

Sales & Book Value

Annual Sales
$48.63 million
Book Value
$6.63 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
67,546,000
Market Cap
$1.01 billion
Next Earnings Date
12/9/2021 (Estimated)
Fiscal Year End
December 31
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.54 out of 5 stars

Medical Sector

92nd out of 1,372 stocks

Pharmaceutical Preparations Industry

37th out of 669 stocks

Analyst Opinion: 3.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -












Atea Pharmaceuticals (NASDAQ:AVIR) Frequently Asked Questions

Is Atea Pharmaceuticals a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atea Pharmaceuticals in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Atea Pharmaceuticals stock.
View analyst ratings for Atea Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Atea Pharmaceuticals?

Wall Street analysts have given Atea Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Atea Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Atea Pharmaceuticals?

Atea Pharmaceuticals saw a decrease in short interest in the month of October. As of October 15th, there was short interest totaling 5,350,000 shares, a decrease of 17.3% from the September 30th total of 6,470,000 shares. Based on an average daily trading volume, of 4,280,000 shares, the days-to-cover ratio is presently 1.3 days. Currently, 8.9% of the company's stock are sold short.
View Atea Pharmaceuticals' Short Interest
.

When is Atea Pharmaceuticals' next earnings date?

Atea Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, December 9th 2021.
View our earnings forecast for Atea Pharmaceuticals
.

How were Atea Pharmaceuticals' earnings last quarter?

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) announced its earnings results on Wednesday, August, 11th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.01 by $0.01. The company had revenue of $60.39 million for the quarter, compared to analysts' expectations of $115.99 million.
View Atea Pharmaceuticals' earnings history
.

What price target have analysts set for AVIR?

5 Wall Street analysts have issued 1-year price objectives for Atea Pharmaceuticals' stock. Their forecasts range from $16.00 to $60.00. On average, they anticipate Atea Pharmaceuticals' stock price to reach $37.75 in the next year. This suggests a possible upside of 210.2% from the stock's current price.
View analysts' price targets for Atea Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Atea Pharmaceuticals' key executives?

Atea Pharmaceuticals' management team includes the following people:
  • Dr. Jean-Pierre Sommadossi Ph.D., Founder, Chairman, CEO & Pres (Age 65, Pay $902.99k)
  • Dr. Janet M.J. Hammond, Chief Devel. Officer (Age 61, Pay $728.32k)
  • Dr. Maria Arantxa Horga M.D., Chief Medical Officer (Age 53, Pay $367.56k)
  • Ms. Andrea J. Corcoran, CFO, Exec. VP of Legal & Sec. (Age 59)
  • Mr. Wayne Foster CPA, CPA, Sr. VP of Fin. & Admin. (Age 53)
  • Ms. Jonae R. Barnes, Sr. VP of Investor Relations & Corp. Communications
  • Mr. Paul J. Fanning, Sr. VP of HR (Age 63)
  • Mr. Steven Good, Exec. VP of Preclinical Science
  • Mr. Adel Moussa Ph.D., Exec. VP of Chemistry
  • Mr. Xiao-Jian Zhou Ph.D., Exec. VP of Early Stage Devel.

When did Atea Pharmaceuticals IPO?

(AVIR) raised $253 million in an IPO on Friday, October 30th 2020. The company issued 11,000,000 shares at a price of $22.00-$24.00 per share. J.P. Morgan, Morgan Stanley, Evercore ISI and William Blair served as the underwriters for the IPO.

What is Atea Pharmaceuticals' stock symbol?

Atea Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVIR."

Who are Atea Pharmaceuticals' major shareholders?

Atea Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Frontier Capital Management Co. LLC (0.22%), Harel Insurance Investments & Financial Services Ltd. (0.02%), Axiom Investment Management LLC (0.01%) and NEXT Financial Group Inc (0.01%).

Which major investors are buying Atea Pharmaceuticals stock?

AVIR stock was acquired by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Harel Insurance Investments & Financial Services Ltd., Axiom Investment Management LLC, and NEXT Financial Group Inc.

How do I buy shares of Atea Pharmaceuticals?

Shares of AVIR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Atea Pharmaceuticals' stock price today?

One share of AVIR stock can currently be purchased for approximately $12.17.

How much money does Atea Pharmaceuticals make?

Atea Pharmaceuticals has a market capitalization of $1.01 billion and generates $48.63 million in revenue each year. The company earns $-10.95 million in net income (profit) each year or ($0.51) on an earnings per share basis.

How many employees does Atea Pharmaceuticals have?

Atea Pharmaceuticals employs 39 workers across the globe.

What is Atea Pharmaceuticals' official website?

The official website for Atea Pharmaceuticals is www.ateapharma.com.

How can I contact Atea Pharmaceuticals?

The company can be reached via phone at 857-284-8891 or via email at [email protected].


This page was last updated on 10/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.